atu027
Nucleic acidexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2009 (NCT00938574)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Serine/threonine-protein kinase N3ANTISENSE INHIBITOR
PKN3 antisense inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- atu027
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01808638 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2013 | FGK Clinical Research GmbH, Granzer Regulatory Consulting & Services, Silence Therapeutics GmbH |
| NCT00938574 | Phase 1 | Jun 1, 2009 | Ruhr University Bochum, Silence Therapeutics GmbH |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Silence Therapeutics GmbH | For profit | 2 | 2 | 2 | 2009 |
| FGK Clinical Research GmbH | For profit | 1 | 0 | 1 | 2013 |
| Granzer Regulatory Consulting & Services | For profit | 1 | 0 | 1 | 2013 |
| Ruhr University Bochum | Academic/Hospital | 1 | 0 | 1 | 2009 |
4 organizations
Page 1 / 1